BLOG
Dr Reddy's Q1FY23 Review: Multiple one-offs in muted Q1 launches to drive recovery
What’s Buzzing:
Dr Reddy's Laboratories’ Q1 revenues were in line with I-direct estimates while margins were a miss on estimates on account of higher commodity prices, adverse leverage on manufacturing overheads, price erosion and adverse forex related impact.
Context:
Revenues grew 6% YoY to Rs 5233 crore, driven by 26% YoY growth in India to Rs 1334 crore. Russia & Other CIS markets grew 4% YoY to Rs 510 crore while Europe also grew 4% YoY to Rs 414 crore. US markets grew 2% YoY to Rs 1781 crore while RoW markets de-grew 8% YoY to Rs 390 crore. PSAI segment posted de-growth of 6% YoY to Rs 709 crore. Gross margins declined 210 bps YoY to 63.5% and EBITDA margins improved 313 bps to 18%. Adjusted EBITDA margins for one-off divestment income was at 14.2%. Subsequently, EBITDA grew 28% YoY to Rs 941 crore. PAT for the quarter was up 224% YoY to Rs 1180 crore on back of settlement income of Rs 563.8 crore.
Our perspective:
Q1FY23 print was marred by one offs in various directions but the actual narrative was on substantial weaker footing. India revenues for Q1FY23 included divestment income of Rs 230.1crore from sale of brands to JB Chemicals and Torrent Pharma. Russia & CIS markets saw poor offtake due to channel inventory normalisation post stocking up in Q4FY22 while the US was muted due to price erosion in some key molecules. Dr Reddy’s is likely to launch 25 products in the US during FY23, including volume limited launch of gRevlimid in September, 2022. We believe, Dr Reddy’s is structurally well placed with likely ramp-up in global generics on back of upcoming launch schedule. The management remains committed to working on cost rationalisation, especially on the SGN&A front for margins improvement.
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Related content
Blogs
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Video
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.